DARA BioSciences, Inc. (DARA)

[LaJollaCA]

Won't be too long.....

--Provided U.S. Food and Drug Administration (FDA), on November 19, 2013,
with additional information requested in support of DARA's request for
orphan drug designation for the Company's Phase 2 development asset,
KRN5500, for the treatment of painful, treatment-refractory, chronic
chemotherapy-induced peripheral neuropathy ("CCIPN").